A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
Clinical trial NCT05821777 · TERMINATED
Trial details
- NCT number
- NCT05821777
- Sponsor
- Centessa Pharmaceuticals (UK) Limited
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-28
- Primary completion
- 2025-01-24
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.